Clinical Trials on Leukemia, Nonlymphoblastic, Acute

Total 18590 results

University of Southern California
National Cancer Institute (NCI)

Withdrawn

Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute Myeloid Leukemia in Remission

Adult Acute Myeloid Leukemia in Remission | Childhood Acute Myeloid Leukemia in Remission

United States
Stanford University

Withdrawn

Midostaurin in Treating Older Patients With Mutated Acute Myeloid Leukemia Post-Transplant

Adult Acute Myeloid Leukemia in Remission | Acute Myeloid Leukemia With Gene Mutations
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Studying DNA in Blood and Bone Marrow Samples From Younger Patients With Acute Myeloid Leukemia

Adult Acute Myeloid Leukemia in Remission | Childhood Acute Myeloid Leukemia in Remission

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Long-term Safety Study of Arsenic Trioxide in Newly Diagnosed, Low-to-intermediate Risk Acute Promyelocytic Leukemia (APL0618)

Acute Promyelocytic Leukemia

Italy
Syros Pharmaceuticals

Suspended

A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Leukemia

United States
Memorial Sloan Kettering Cancer Center
National Heart, Lung, and Blood Institute (NHLBI); Northwestern University; University... and other collaborators

Completed

Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy

Acute Promyelocytic Leukemia

United States, Canada
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

AIDA 2000 Guidelines

Acute Promyelocytic Leukemia

Italy
University Hospital, Lille

Completed

Transplant T CD4+ CCR7+ In Hematopoietic Stem Cells Allograft (CCR7-CD4-DPL)

Acute Myeloblastic Leukemia

France
Associazione Italiana Ematologia Oncologia Pediatrica

Unknown

Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia

Acute Promyelocytic Leukemia

Italy
University of Southern California
Sponsor Name Pending

Withdrawn

New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia

Acute Promyelocytic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Biomarkers in Tissue Samples From Patients With Acute Promyelocytic Leukemia

Leukemia
CytRx

Completed

Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL (STAR-1)

Acute Promyelocytic Leukemia

United States
Technische Universität Dresden

Unknown

AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia

Leukemia, Promyelocytic, Acute

Germany
Christian Medical College, Vellore, India
Ministry of Science and Technology, India

Unknown

Single Agent Arsenic Trioxide in the Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (IAPLSG04)

Acute Promyelocytic Leukemia

India
University of California, Irvine
Pfizer; Jazz Pharmaceuticals

Recruiting

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

Acute Myeloid Leukemia With Myelodysplasia-Related Changes | Acute Myelogenous Leukemia (AML) Due to Therapy

United States
Beijing Boren Hospital

Recruiting

Phase I/II Study of Enhanced CD33 CAR T Cells in Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapse Leukemia

China
Shanghai Fosun Pharmaceutical Industrial Development...

Terminated

A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML

Advanced Cancer | Solid Tumors | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States, Australia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Completed

Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
University Hospital, Bordeaux

Recruiting

Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia (COALA)

Acute Myeloblastic Leukemia

France
Igenica Biotherapeutics, Inc.

Completed

A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML

Acute Myeloid Leukemia | Acute Myelogenous Leukemia

United States
Acute Leukemia French Association
Assistance Publique - Hôpitaux de Paris

Withdrawn

ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML) (ALFA-0703)

Acute Myeloid Leukemia

France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Chronic Myelomonocytic Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic... and other conditions

United States
Second Affiliated Hospital of Xi'an Jiaotong University
Nanjing Legend Biotech Co.

Terminated

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia

Acute Myeloid Leukemia | Acute Leukemia | Acute Leukemia in Relapse | Relapsed or Refractory Acute Leukemia

China
University of Washington
National Cancer Institute (NCI)

Completed

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia... and other conditions

United States
National Cancer Institute (NCI)

Completed

Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia

Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Recurrent Adult Acute Lymphoblastic Leukemia | Untreated Adult Acute Lymphoblastic Leukemia

United States
University Hospital Tuebingen

Not yet recruiting

Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients (AML-VAC-XS15)

Acute Myeloid Leukemia, Adult
University Hospital, Caen

Not yet recruiting

Relation Between Venetoclax Plasma Concentration and Remission in Adults With Acute Myeloid Leukemia (PREDICLAX)

Adult Acute Myeloid Leukemia
First Affiliated Hospital of Zhejiang University

Recruiting

Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia (CHA)

Acute Myeloid Leukemia, Adult

China
K-Group Alpha, Inc., a wholly owned subsidiary...

Recruiting

Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

United States
Sunshine Lake Pharma Co., Ltd.

Not yet recruiting

A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML

Acute Myeloid Leukemia, Adult

China
Shanghai Jiao Tong University School of Medicine

Recruiting

Aza-Ven Followed by Reduced Toxicity Conditioning Regimen (MBF) as Salvage Therapy for Refractory AML.

Refractory Acute Myeloid Leukemia

China
AbbVie

Recruiting

Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

Korea, Republic of
Hospices Civils de Lyon

Recruiting

Pharmacokinetics Variability of Posaconazole (PCZ) and Its Glucuronide Metabolite During Induction and Consolidation Treatments in Patients With Acute Myeloid Leukemia (AML): a Covariate Analysis With the Tablets Formulation and Evaluation of the Potential Risk of Hepatotoxicity (Posa-Pk)

Leukemia, Myeloid, Acute

France
Celgene
AbbVie

Completed

A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML) (OMNIVERSE)

Leukemia, Myeloid, Acute

United States, Australia
Sumitomo Pharma America, Inc.

Terminated

Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy

Acute Myeloid Leukemia (AML)

United States
AbbVie

Completed

A Study of the Effectiveness of Venetoclax Tablets in Adult Acute Myeloid Leukemia Participants Ineligible for Standard Induction Therapy in Russian Federation (INNOVATE)

Acute Myeloid Leukemia (AML)

Russian Federation
Moleculin Biotech, Inc.

Completed

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

Poland
Moleculin Biotech, Inc.

Completed

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States
Sunshine Lake Pharma Co., Ltd.

Terminated

A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (AML)

China
Grupo Cooperativo de Estudio y Tratamiento de las...

Completed

Prospective Study of Mylotarg and G-CSF in Acute Myeloid Leukemia Treatment

Novo Acute Myeloid Leukemia

Spain
Celularity Incorporated

Terminated

A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States
Therapeutic Advances in Childhood Leukemia Consortium
Genzyme, a Sanofi Company

Terminated

T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)

Relapsed Acute Myelogenous Leukemia

United States
Stanford University
Genzyme, a Sanofi Company

Terminated

Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

Leukemia | Leukemia, Myeloid | Acute Myeloid Leukemia (AML)

United States
Weill Medical College of Cornell University

Terminated

Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML (Pacritinib)

Acute Myeloid Leukemia (AML)

United States
Institute of Hematology & Blood Diseases Hospital

Completed

Efficacy Analysis of Comparison of CAMS（Chinese Academy of Medical Sciences）-2005 Trial and CAMS-2009 Trial for Pediatric Acute Myeloid Leukemia

Acute Myeloid Leukemia, Pediatric

China
Chunyan Ji
Qingdao University; Qianfoshan Hospital; Jinan Central Hospital; Jining Medical... and other collaborators

Unknown

Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia, Adult
Sanofi

Terminated

Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia (ISLAY)

T-cell Type Acute Leukemia-Precursor | T-lymphoblastic Lymphoma/Leukaemia

Hungary, United States, Finland, France, Italy, Lithuania, Russian Federation
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

Recurrent Mixed Phenotype Acute Leukemia | Acute Leukemia of Ambiguous Lineage | Acute Undifferentiated Leukemia | Acute Bilineal Leukemia | Acute Biphenotypic Leukemia | Mixed Phenotype Acute Leukemia | Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified | Mixed Phenotype Acute Leukemia...

United States

Clinical Trials on Leukemia, Nonlymphoblastic, Acute

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Djibouti

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations